{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:50:24Z","timestamp":1781585424130,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1025637"],"award-info":[{"award-number":["APP1025637"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Postgraduate"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.pupt.2017.04.006","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T03:17:16Z","timestamp":1492139836000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Doxofylline does not increase formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of anti-inflammatory effect"],"prefix":"10.1016","volume":"45","author":[{"given":"Brijeshkumar S.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kugel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Baehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaina J.","family":"Ammit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pupt.2017.04.006_bib1","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1164\/rccm.201302-0388PP","article-title":"Theophylline","volume":"188","author":"Barnes","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2017.04.006_bib2","series-title":"Xanthines and Phosphodiesterase Inhibitors, Handbook of Experimental Pharmacology","author":"Spina","year":"2016"},{"issue":"7","key":"10.1016\/j.pupt.2017.04.006_bib3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.200906-0937OC","article-title":"Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease","volume":"182","author":"To","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2017.04.006_bib4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaci.2012.12.1564","article-title":"Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease","volume":"131","author":"Barnes","year":"2013","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2017.04.006_bib5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3892\/mmr.2014.2188","article-title":"Theophylline improves lipopolysaccharide-induced alveolarization arrest through inflammatory regulation","volume":"10","author":"He","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.pupt.2017.04.006_bib6","doi-asserted-by":"crossref","first-page":"e91083","DOI":"10.1371\/journal.pone.0091083","article-title":"Lipopolysaccharide induces up-regulation of TGF-alpha through HDAC2 in a rat model of bronchopulmonary dysplasia","volume":"9","author":"Ni","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pupt.2017.04.006_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0035-1555611","article-title":"Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: what does the future hold?","volume":"36","author":"Barnes","year":"2015","journal-title":"Seminars Respir. Crit. care Med."},{"issue":"6","key":"10.1016\/j.pupt.2017.04.006_bib8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1165\/rcmb.2015-0308OC","article-title":"Theophylline represses IL-8 secretion from airway smooth muscle cells independently of phosphodiesterase inhibition. Novel role as a protein phosphatase 2A activator","volume":"54","author":"Patel","year":"2016","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.pupt.2017.04.006_bib9","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1165\/rcmb.2014-0344OC","article-title":"Inhibitors of phosphodiesterase 4, but not phosphodiesterase 3, increase beta2-agonist-induced expression of antiinflammatory mitogen-activated protein kinase phosphatase 1 in airway smooth muscle cells","volume":"52","author":"Patel","year":"2015","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.pupt.2017.04.006_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.pupt.2010.04.002","article-title":"Doxofylline: a \u201cnovofylline\u201d","volume":"23","author":"Page","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pupt.2017.04.006_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pupt.2011.10.007","article-title":"The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism","volume":"25","author":"van Mastbergen","year":"2012","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.pupt.2017.04.006_bib12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pupt.2014.01.001","article-title":"Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse","volume":"27","author":"Riffo-Vasquez","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pupt.2017.04.006_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1006\/pulp.1995.1006","article-title":"The maintenance of functional activity in human isolated bronchus after cryopreservation","volume":"8","author":"Johnson","year":"1995","journal-title":"Pulm. Pharmacol."},{"issue":"9","key":"10.1016\/j.pupt.2017.04.006_bib14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/all.12449","article-title":"TLR2 activation causes tachyphylaxis to beta2 -agonists in\u00a0vitro and ex\u00a0vivo: modelling bacterial exacerbation","volume":"69","author":"Alkhouri","year":"2014","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.pupt.2017.04.006_bib15","first-page":"107","article-title":"Oral doxophylline in patients with chronic obstructive pulmonary disease","volume":"35","author":"Villani","year":"1997","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.pupt.2017.04.006_bib16","first-page":"Cr297","article-title":"Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma \u2013 a double-blind randomized placebo-controlled multicentre clinical trial","volume":"8","author":"Goldstein","year":"2002","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"issue":"10","key":"10.1016\/j.pupt.2017.04.006_bib17","first-page":"1681","article-title":"Doxofylline and theophylline: a comparative clinical study","volume":"6","author":"Akram","year":"2012","journal-title":"J.\u00a0Clin. Diagn. Res. JCDR"},{"issue":"2","key":"10.1016\/j.pupt.2017.04.006_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.clinthera.2014.12.008","article-title":"Assessment of montelukast, doxofylline, and tiotropium with budesonide for the treatment of asthma: which is the best among the second-line treatment? A randomized trial","volume":"37","author":"Rajanandh","year":"2015","journal-title":"Clin. Ther."},{"issue":"5","key":"10.1016\/j.pupt.2017.04.006_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1515\/jbcpp-2015-0006","article-title":"Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease","volume":"26","author":"Lal","year":"2015","journal-title":"J.\u00a0Basic Clin. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2017.04.006_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.chest.2016.04.011","article-title":"Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial","volume":"150","author":"Cosio","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.pupt.2017.04.006_bib21","first-page":"L1283","article-title":"IL-17A acts via p38 MAPK to increase stability of TNF-alpha-induced IL-8 mRNA in human ASM","volume":"290","author":"Henness","year":"2006","journal-title":"Am. J. Physiol."},{"issue":"3","key":"10.1016\/j.pupt.2017.04.006_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.bbamcr.2009.12.007","article-title":"Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: mechanism of action and effect on cytokine secretion","volume":"1803","author":"Moutzouris","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.pupt.2017.04.006_bib23","doi-asserted-by":"crossref","first-page":"L838","DOI":"10.1152\/ajplung.00317.2011","article-title":"TLR2 ligand engagement upregulates airway smooth muscle TNFalpha-induced cytokine production","volume":"302","author":"Manetsch","year":"2012","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"2\u20133","key":"10.1016\/j.pupt.2017.04.006_bib24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0014-2999(89)90721-8","article-title":"Doxofylline exerts a prophylactic effect against bronchoconstriction and pleurisy induced by PAF","volume":"165","author":"Franzone","year":"1989","journal-title":"Eur. J. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.pupt.2017.04.006_bib25","first-page":"15","article-title":"Effects of oral doxofylline on inflammatory changes and altered cell proliferation in chronic obstructive bronchitis","volume":"4","author":"Cogo","year":"2000","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"19","key":"10.1016\/j.pupt.2017.04.006_bib26","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa041892","article-title":"Decreased histone deacetylase activity in chronic obstructive pulmonary disease","volume":"352","author":"Ito","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"5","key":"10.1016\/j.pupt.2017.04.006_bib27","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1183\/09031936.00158208","article-title":"Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study","volume":"33","author":"Spears","year":"2009","journal-title":"Eur. Respir. J."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553916301870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553916301870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T15:43:58Z","timestamp":1719157438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553916301870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":27,"alternative-id":["S1094553916301870"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2017.04.006","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxofylline does not increase formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of anti-inflammatory effect","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2017.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}